Benitec Biopharma (BNTC) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $8.11, -4.14% vs the prior close of $8.46.
- Volume 158.56K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BNTC slides 4.1% to $8.11, a 52-week low. Closed at $8.11, -4.14% vs the prior close of $8.46. Day range $8.06–$8.47, opened at $8.47.
BNTC daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — BNTC slides 4.1% to $8.11, a 52-week low
- Closed at $8.11, -4.14% vs the prior close of $8.46. Day range $8.06–$8.47, opened at $8.47.
- Volume was 158.56K shares, 0.9x its 50-day average of 182.51K.
- Price is -28.0% vs its 50-day average ($11.26) and -30.8% vs its 200-day average ($11.72).
- 52-week range $8.06–$16.76; today's close sits at 1% of that range, 51.6% below the 52-week high.
Oct 15, 2026 — BNTC rises 2.1% to $8.46
- Closed at $8.46, +2.05% vs the prior close of $8.29. Day range $8.34–$8.76, opened at $8.37.
- Volume was 153.70K shares, 0.8x its 50-day average of 181.34K.
- Price is -25.6% vs its 50-day average ($11.36) and -28.0% vs its 200-day average ($11.75).
- 52-week range $8.25–$16.76; today's close sits at 2% of that range, 49.5% below the 52-week high.
Oct 14, 2026 — BNTC slides 3.9% to $8.29, a 52-week low
- Closed at $8.29, -3.94% vs the prior close of $8.63. Day range $8.25–$9.07, opened at $8.52.
- Volume was 162.50K shares, 0.9x its 50-day average of 179.39K.
- Price is -27.6% vs its 50-day average ($11.45) and -29.6% vs its 200-day average ($11.77).
- 52-week range $8.25–$16.76; today's close sits at 0% of that range, 50.5% below the 52-week high.
Oct 13, 2026 — BNTC slides 4.9% to $8.63, a 52-week low
- Closed at $8.63, -4.85% vs the prior close of $9.07. Day range $8.51–$9.08, opened at $9.08.
- Volume was 151.40K shares, 0.8x its 50-day average of 178.40K.
- Price is -25.2% vs its 50-day average ($11.53) and -26.8% vs its 200-day average ($11.80).
- 52-week range $8.51–$16.76; today's close sits at 1% of that range, 48.5% below the 52-week high.
Oct 12, 2026 — BNTC rises 2.3% to $9.07
- Closed at $9.07, +2.25% vs the prior close of $8.87. Day range $8.75–$9.25, opened at $8.90.
- Volume was 200.90K shares, 1.1x its 50-day average of 176.53K.
- Price is -21.8% vs its 50-day average ($11.60) and -23.3% vs its 200-day average ($11.82).
- 52-week range $8.52–$16.76; today's close sits at 7% of that range, 45.9% below the 52-week high.
Oct 9, 2026 — BNTC rises 1.4% to $8.87
- Closed at $8.87, +1.37% vs the prior close of $8.75. Day range $8.71–$9.03, opened at $8.72.
- Volume was 73.00K shares, 0.4x its 50-day average of 175.97K — lighter than usual.
- Price is -23.9% vs its 50-day average ($11.66) and -25.1% vs its 200-day average ($11.84).
- 52-week range $8.52–$16.76; today's close sits at 4% of that range, 47.1% below the 52-week high.
Oct 8, 2026 — BNTC dips 2.7% to $8.75, a 52-week low, 3 down days in a row
- Closed at $8.75, -2.67% vs the prior close of $8.99. Day range $8.61–$8.97, opened at $8.86.
- Volume was 234.90K shares, 1.4x its 50-day average of 172.33K.
- Price is -25.3% vs its 50-day average ($11.72) and -26.2% vs its 200-day average ($11.85).
- 52-week range $8.52–$16.76; today's close sits at 3% of that range, 47.8% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — BNTC ends flat (-0.1%) to $8.99
- Closed at $8.99, -0.11% vs the prior close of $9.00. Day range $8.80–$9.27, opened at $8.81.
- Volume was 190.10K shares, 1.1x its 50-day average of 170.08K.
- Price is -23.7% vs its 50-day average ($11.78) and -24.3% vs its 200-day average ($11.87).
- 52-week range $8.52–$16.76; today's close sits at 6% of that range, 46.4% below the 52-week high.
Oct 6, 2026 — BNTC dips 2.5% to $9.00
- Closed at $9.00, -2.49% vs the prior close of $9.23. Day range $8.62–$9.56, opened at $9.32.
- Volume was 217.20K shares, 1.3x its 50-day average of 167.05K.
- Price is -24.0% vs its 50-day average ($11.84) and -24.2% vs its 200-day average ($11.88).
- 52-week range $8.52–$16.76; today's close sits at 6% of that range, 46.3% below the 52-week high.
Oct 5, 2026 — BNTC rises 2.8% to $9.23 on 3.7x normal volume
- Closed at $9.23, +2.78% vs the prior close of $8.98. Day range $8.52–$9.99, opened at $9.00.
- Volume was 584.20K shares, 3.7x its 50-day average of 158.60K — unusually heavy trading.
- Price is -22.4% vs its 50-day average ($11.89) and -22.4% vs its 200-day average ($11.89).
- 52-week range $8.52–$16.76; today's close sits at 9% of that range, 44.9% below the 52-week high.
- SEC filings that day: 8-K.
Oct 2, 2026 — BNTC slides 6.3% to $8.98, a 52-week low
- Closed at $8.98, -6.26% vs the prior close of $9.58. Day range $8.92–$9.88, opened at $9.71.
- Volume was 135.10K shares, 0.9x its 50-day average of 158.46K.
- Price is -24.8% vs its 50-day average ($11.94) and -24.6% vs its 200-day average ($11.91).
- 52-week range $8.92–$16.76; today's close sits at 1% of that range, 46.4% below the 52-week high.
BNTC latest news & SEC filings
Every SEC filing by or about BNTC in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 4.01 — Changed its outside auditor.
Sep 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 4.01 — Changed its outside auditor.
Sep 21, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Sep 14, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 14, 2026 · Form 10-K — Annual report
Annual report (audited full-year financial statements and business review)
Fiscal year ended Jun 30, 2026:
- Net income: -$45.55M (prior year -$37.92M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.98 (prior year -$1.05) (loss narrowed vs Jun 30, 2025)
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade BNTC
- Last results release: Sep 14, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Feb 12, 2026, Nov 14, 2025. Based on that rhythm, the next report is likely around Dec 14, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.07% (largest 10.2%). That is a volatile stock.
- Liquidity: about 196.66K shares (≈$1.59M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $8.11 vs a range of $8.06–$16.76 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Aaron Cowen bought 65,800 shares on Dec 29, 2025.
- Latest filings: 8-K Oct 5, 2026; 8-K Sep 30, 2026; 8-K Sep 24, 2026.
- Share count: 34.88M shares outstanding (Sep 4, 2026), +32.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
BNTC market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 8.47 | 8.47 | 8.06 | 8.11 | 158.56K |
| Oct 15, 2026 | 8.37 | 8.76 | 8.34 | 8.46 | 153.70K |
| Oct 14, 2026 | 8.52 | 9.07 | 8.25 | 8.29 | 162.50K |
| Oct 13, 2026 | 9.08 | 9.08 | 8.51 | 8.63 | 151.40K |
| Oct 12, 2026 | 8.90 | 9.25 | 8.75 | 9.07 | 200.90K |
| Oct 9, 2026 | 8.72 | 9.03 | 8.71 | 8.87 | 73.00K |
| Oct 8, 2026 | 8.86 | 8.97 | 8.61 | 8.75 | 234.90K |
| Oct 7, 2026 | 8.81 | 9.27 | 8.80 | 8.99 | 190.10K |
| Oct 6, 2026 | 9.32 | 9.56 | 8.62 | 9.00 | 217.20K |
| Oct 5, 2026 | 9.00 | 9.99 | 8.52 | 9.23 | 584.20K |
| Oct 2, 2026 | 9.71 | 9.88 | 8.92 | 8.98 | 135.10K |
| Oct 1, 2026 | 9.94 | 10.17 | 9.47 | 9.58 | 103.10K |
| Sep 30, 2026 | 9.83 | 10.13 | 9.64 | 10.00 | 146.00K |
| Sep 29, 2026 | 10.17 | 10.17 | 9.65 | 9.75 | 111.00K |
| Sep 28, 2026 | 9.57 | 10.04 | 9.31 | 10.02 | 152.80K |
| Sep 25, 2026 | 9.70 | 9.80 | 9.31 | 9.59 | 107.00K |
| Sep 24, 2026 | 9.74 | 10.41 | 9.26 | 9.64 | 196.70K |
| Sep 23, 2026 | 10.92 | 11.32 | 9.49 | 9.83 | 644.20K |
| Sep 22, 2026 | 10.97 | 11.36 | 10.61 | 10.95 | 88.90K |
| Sep 21, 2026 | 11.12 | 11.14 | 10.74 | 10.88 | 121.90K |
About Benitec Biopharma
Benitec Biopharma (BNTC) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in HAYWARD, CA. State of incorporation: DE. Fiscal year ends June 30. SEC CIK 1808898.
BNTC board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Master Fund, Ltd. Averill | Director | Dec 29, 2025 |
| J Kevin Buchi | Director | Jun 30, 2026 |
| Jerel A. Banks | Chief Executive Officer | Nov 20, 2025 |
| Megan Boston | Chief Financial Officer | Nov 20, 2025 |
| Aaron Cowen | Director | Dec 29, 2025 |
| Peter Francis | Director | Dec 3, 2025 |
| David Matthew Friedman | Director | May 28, 2026 |
| Sharon Mates | Director | Jan 26, 2026 |
| Kishan Mehta | Director | Dec 3, 2025 |
| Capital Management, Llc Suvretta | Director | Dec 29, 2025 |
| Edward F Smith | Director | Dec 3, 2025 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jerel A. Banks | Chief Executive Officer | Nov 20, 2025 |
| Megan Boston | Chief Financial Officer | Nov 20, 2025 |
| Sophie Mukadam | Chief Operating Officer | Nov 20, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Dec 29, 2025 | Aaron Cowen | Buy | 65,800 | $13.44 |
| Dec 29, 2025 | Aaron Cowen | Buy | 11,587 | $13.44 |
| Dec 29, 2025 | Aaron Cowen | Buy | 65,800 | $13.44 |
| Dec 29, 2025 | Aaron Cowen | Buy | 11,587 | $13.44 |
| Dec 29, 2025 | Master Fund, Ltd. Averill | Buy | 65,800 | $13.44 |
| Dec 29, 2025 | Master Fund, Ltd. Averill | Buy | 11,587 | $13.44 |
| Dec 29, 2025 | Master Fund, Ltd. Averill | Buy | 65,800 | $13.44 |
| Dec 29, 2025 | Master Fund, Ltd. Averill | Buy | 11,587 | $13.44 |
| Dec 29, 2025 | Madison Master Fund, Ltd. Averill | Buy | 65,800 | $13.44 |
| Dec 29, 2025 | Madison Master Fund, Ltd. Averill | Buy | 11,587 | $13.44 |
| Dec 29, 2025 | Madison Master Fund, Ltd. Averill | Buy | 65,800 | $13.44 |
| Dec 29, 2025 | Madison Master Fund, Ltd. Averill | Buy | 11,587 | $13.44 |
| Dec 29, 2025 | Capital Management, Llc Suvretta | Buy | 65,800 | $13.44 |
| Dec 29, 2025 | Capital Management, Llc Suvretta | Buy | 11,587 | $13.44 |
| Dec 29, 2025 | Capital Management, Llc Suvretta | Buy | 65,800 | $13.44 |
BNTC financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Jun 30, 2026 | — | $-45.55M | -0.98 | $-16.52M |
| Jun 30, 2025 | — | $-37.92M | -1.05 | $-23.59M |
| Jun 30, 2024 | — | $-21.75M | -1.22 | $-19.40M |
| Jun 30, 2023 | — | $-19.56M | -14.12 | $-18.01M |
| Jun 30, 2022 | — | $-18.21M | -37.88 | $-15.90M |
Latest balance sheet: total assets $182.62M, total liabilities $5.61M, cash $179.97M (as of Jun 30, 2026).
BNTC earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Sep 14, 2026 | 8-K Item 2.02 (results) | $12.08 |
| May 14, 2026 | 8-K Item 2.02 (results) | $11.85 |
| Feb 12, 2026 | 8-K Item 2.02 (results) | $11.34 |
| Nov 14, 2025 | 8-K Item 2.02 (results) | $13.16 |
| Sep 22, 2025 | 8-K Item 2.02 (results) | $13.51 |
| May 14, 2025 | 8-K Item 2.02 (results) | $13.58 |
| Feb 14, 2025 | 8-K Item 2.02 (results) | $11.25 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $10.40 |
| Sep 26, 2024 | 8-K Item 2.02 (results) | — |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
| Feb 13, 2024 | 8-K Item 2.02 (results) | — |
| Nov 13, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on BNTC
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.